Asthma study aims to better understand uncontrolled disease in daily life
NCT ID NCT06299306
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at adults with severe uncontrolled asthma in Germany to see how well their asthma was controlled over 12 months. Researchers used a simple questionnaire called AIRQ® to track symptoms, medication use, and doctor visits. The goal was to gather real-world information to help identify patients who need better care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
19 people
The number who actually took part.
- Started
-
May 2024
- Finished
-
Nov 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population is composed of severe asthma patients within GINA/NVL (Global Initiative for Asthma/ Nationale Versorgungsleitlinie) steps 4 or 5 with uncontrolled disease (including patients on biologics but without any prescribed oral corticosteroids).
- Ages
-
18 to 120 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * ≥18 years of age at the time of consent * Therapy within GINA/NVL steps 4 or 5 and uncontrolled disease in the previous 12 months as per the healthcare provider's assessment * Willing and able to provide written informed consent indicating that they understand the purpose and procedures required for the study and are willing to participate * Able to read, understand, and speak German sufficiently to complete all the questionnaires Exclusion Criteria: * According to the assessment of the study physician: cognitive impairment, psychiatric diseases, severe hearing or vision impairment, insufficient knowledge of the German language, if these factors could influence the ability to provide written consent and correct completion and assessment of the questionnaires. * Current participation in an observational study that might, in the investigator's opinion, influence the assessment for the current study, or participation in a randomized clinical trial in the last 30 days.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Asthma, bronchial are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Berlin, Germany
-
Research Site
Blankenhein, Germany
-
Research Site
Bonn, Germany
-
Research Site
Fürstenwalde, Germany
-
Research Site
Gauting, Germany
-
Research Site
Weißenburg, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for teens with severe asthma? dupilumab under the microscope
- New asthma drug shows promise in reducing severe attacks
- Sleep apnea device may ease severe asthma symptoms
- New asthma drug aims to stop attacks in severe cases
- Italian asthma study tracks new biologic in real life
- New asthma drug could help kids breathe easier